Imagen de Portada
Código QR

A Meta-Analysis of Randomized Clinical Trials Assessing the Efficacy of PARP Inhibitors in Metastatic Castration-Resistant Prostate Cancer.

Prostate cancer ranks as the second most common malignancy in males. Prostate cancer progressing on androgen deprivation therapy (ADT) is castration-resistant prostate cancer (CRPC). Poly-ADP ribose polymerase (PARP) inhibitors (PARPis) have been at the forefront of the treatment of CRPC. We aim to...

Descripción completa

Publicado en:Current Oncology Vol. 30; no. 10; pp. 9262 - 9276
Autores principales: Alameddine, Zakaria, Niazi, Muhammad Rafay Khan, Rajavel, Anisha, Behgal, Jai, Keesari, Praneeth Reddy, Araji, Ghada, Mustafa, Ahmad, Wei, Chapman, Jahangir, Abdullah, Terjanian, Terenig O
Formato: Journal Article
Publicado: MDPI Oct2023
Acceso en línea:Ver este registro en EBSCOhost
fields @attributes:
  recordID: 1
pdfLink:
plink: https://search.ebscohost.com/login.aspx?direct=true&db=ccm&AN=173265838&site=ehost-live
header:
  @attributes:
    shortDbName: ccm
    uiTerm: 173265838
    longDbName: CINAHL Complete
    uiTag: AN
  controlInfo:
    bkinfo:
    dissinfo:
    jinfo:
      jid:
        11980052
        5EKK
      jtl: Current Oncology
      issn: 11980052
      maglogo: N
    pubinfo:
      dt: Oct2023
      vid: 30
      iid: 10
      pid: 97109
      pub: MDPI
    artinfo:
      ui:
        173265838
        10.3390/curroncol30100669
        173265838
      ppf: 9262
      ppct: 14
      formats:
        fmt:
          – @attributes:
              type: T
          – @attributes:
              type: P
      tig:
        atl: A Meta-Analysis of Randomized Clinical Trials Assessing the Efficacy of PARP Inhibitors in Metastatic Castration-Resistant Prostate Cancer.
      aug:
        au:
          Alameddine, Zakaria
          Niazi, Muhammad Rafay Khan
          Rajavel, Anisha
          Behgal, Jai
          Keesari, Praneeth Reddy
          Araji, Ghada
          Mustafa, Ahmad
          Wei, Chapman
          Jahangir, Abdullah
          Terjanian, Terenig O
        affil: Staten Island University Hospital, Staten Island, NY 10305, USA
      sug:
      ab: Prostate cancer ranks as the second most common malignancy in males. Prostate cancer progressing on androgen deprivation therapy (ADT) is castration-resistant prostate cancer (CRPC). Poly-ADP ribose polymerase (PARP) inhibitors (PARPis) have been at the forefront of the treatment of CRPC. We aim to better characterize the progression-free survival (PFS) and overall survival (OS) in metastatic CRPC patients treated with PARPis. A systemic review search was conducted using National Clinical Trial (NCT), PubMed, Embase, Scopus, and Central Cochrane Registry. The improvement in overall survival was statistically significant, favoring PARPis (hazard ratio (HR) 0.855; 95% confidence interval (CI) 0.752–0.974; p = 0.018). The improvement in progression-free survival was also statistically significant, with results favoring PARPis (HR 0.626; 95%CI 0.566–0.692; p = 0.000). In a subgroup analysis, similar results were observed where the efficacy of PARPis was evaluated in a subgroup of patients without homologous recombination repair (HRR) gene mutation, which showed improvement in PFS favoring PARPis (HR 0.747; 95%CI 0.0.637–0.877; p = 0.000). Our meta-analysis of seven RCTs showed that PARPis significantly increased PFS and OS when used with or without antihormonal agents like abiraterone or enzalutamide.
      pubtype: Academic Journal
      doctype: Journal Article
      ougenre: Article
    language: English
    refInfo:
    holdings:
      @attributes:
        islocal: N